F-star Therapeutics's receivables is $8.1M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (September 2022), FSTX shows a receivables of $8.1M. That compares with $1.9M in the prior-year period — up 320.3% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, FSTX's receivables is now $8.1M (was $1.9M) — a 320.3% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether F-star Therapeutics is outperforming or lagging.
Tracking FSTX's receivables over time shows whether F-star Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $8.1M That compares with $1.9M in the prior-year period — up 320.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this receivables page, Stockcircle has F-star Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $8.1M) with ownership activity and broader fundamentals.
F-star Therapeutics's receivables is $8.1M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.